N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
N/A N=234 The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)
Hemorrhage
Primary: Hemostatic Success at 5 Minutes — 109; 103 Participants — p=<0.0001
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
N/A N=70 U.S. Study of Fibrocaps in Surgical Hemostasis
Postoperative Hemorrhage
Primary: Mean Time to Hemostasis (TTH) — 1.9; 4.8 minutes — p=<0.001
Phase 1 N=27 HEMOBLAST Pilot Clinical Investigation
Hemostasis
Primary: Mean Paired Kappa Statistic for the Assignment of SBSS Scores by 2 Investigators — 0.7754 Kappa statistic
Phase 4 N=150 EVARREST™ Fibrin Sealant Patch Post-Market Study
Hemorrhage · Soft Tissue Bleeding
Primary: Safety Parameter - Incidence of Thromboembolic Events — 2; 7 Participants
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Phase 3 N=253 TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Hemorrhage
Primary: Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes — 80.7; 50.0; 87.5; 44.4 percentage of participants — p=<0.001
Phase 2 N=70 Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection
Bleeding (Oozing) in Hepatic Resection
Primary: Percentage of Participants With Intraoperative Hemostasis at 4 Minutes After Treatment Application — 82.9; 37.1 percentage of participants — p=<0.001
N/A N=50 Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery
Liver Disease
Primary: Median Time to Achieve Hemostasis Following Application of Study Treatment. — 1; 3 Minutes — p=<0.0001
Phase 3 N=102 The EVARREST® Fibrin Sealant Patch Liver Study
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
N/A N=258 HEMOBLAST Pivotal Clinical Investigation
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis — 148; 61 Participants — p=<0.0001
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
N/A N=236 Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting
Hemostasis · Bleeding
Primary: The Time to Hemostasis Measured From Start of Study Treatment to the Achievement of Hemostasis at the Target Bleeding Site (TBS), or to the End of the 10-minute…
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
N/A N=482 Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
Hemorrhage
Primary: Assessment of TachoSil® by the Surgeon With Respect to Handling, Utility and Satisfaction in the Operation, Documented Using 10 Point Numerical Rating Scales — 2.54…
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=324 Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
Blood Loss, Surgical
Primary: Number of Participants With Achievement of Hemostasis at 7 Minutes — 145; 149 Participants — p=0.005
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
Phase 3 N=325 Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries
Parenchymous Tissue Surgical Bleeding
Primary: Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start — 92.8; 80.5 Percent of subjects achieving hemostasis
Phase 4 N=18 Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Myomectomy; Surgical Blood Loss
Primary: Surgical Blood Loss — 761; 691 ml
Phase 4 N=140 Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty
Hip Arthritis
Primary: Number of Patients Managed With Blood Transfusion — 15; 14 participants
Phase 2 N=181 Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis by Five Minutes After Treatment Start at the TBS — 75.0; 75.0; 73.9; 82.5 percent of subjects achieving hemostasis
Phase 4 N=252 The Bioseal Vascular Study
Cardiovascular Bleeding · Vascular Bleeding · Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 10 Minutes Following the Completion of Treatment Application. — 96; 88.2 percentage of patients
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001